Literature DB >> 15375563

Construction and expression of a bispecific single-chain antibody that penetrates mutant p53 colon cancer cells and binds p53.

Richard H Weisbart1, Rika Wakelin, Grace Chan, Carl W Miller, Phillip H Koeffler.   

Abstract

A bispecific, single-chain antibody Fv fragment (Bs-scFv) was constructed from a single-chain Fv fragment of mAb 3E10 that penetrates living cells and localizes in the nucleus, and a single-chain Fv fragment of a non-penetrating antibody, mAb PAb421 that binds the C-terminal of p53. PAb421 binding restores wild-type functions of some p53 mutants, including those of SW480 human colon cancer cells. The Bs-scFv penetrated SW480 cells and was cytotoxic, suggesting an ability to restore activity to mutant p53. COS-7 cells (monkey kidney cells with wild-type p53) served as a control since they are unresponsive to PAb421 due to the presence of SV40 large T antigen that inhibits binding of PAb421 to p53. Bs-scFv penetrated COS-7 cells but was not cytotoxic, thereby eliminating non-specific toxicity of Bs-scFv unrelated to binding p53. A single mutation in CDR1 of PAb421 VH eliminated binding of the Bs-scFv to p53 and abrogated cytotoxicity for SW480 cells without altering cellular penetration, further supporting the requirement of PAb421 binding to p53 for cytotoxicity. Our study demonstrates the use of an antibody that penetrates living cells in the design of a bispecific single chain antibody to target and restore the function of an intracellular protein.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15375563

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  7 in total

1.  Recombinant Fv-Hsp70 protein mediates neuroprotection after focal cerebral ischemia in rats.

Authors:  Xinhua Zhan; Bradley P Ander; Isaac H Liao; James E Hansen; Chester Kim; Douglas Clements; Richard H Weisbart; Robert N Nishimura; Frank R Sharp
Journal:  Stroke       Date:  2010-01-14       Impact factor: 7.914

Review 2.  Emerging Non-Canonical Functions and Regulation by p53: p53 and Stemness.

Authors:  David J Olivos; Lindsey D Mayo
Journal:  Int J Mol Sci       Date:  2016-11-26       Impact factor: 5.923

Review 3.  Targeted Intracellular Delivery of Antibodies: The State of the Art.

Authors:  Tatiana A Slastnikova; A V Ulasov; A A Rosenkranz; A S Sobolev
Journal:  Front Pharmacol       Date:  2018-10-24       Impact factor: 5.810

Review 4.  Bispecific Antibodies Progression in Malignant Melanoma.

Authors:  Juan Tang; Youling Gong; Xuelei Ma
Journal:  Front Pharmacol       Date:  2022-03-23       Impact factor: 5.810

Review 5.  Antibody-Based Approaches to Target Pancreatic Tumours.

Authors:  Marie Sorbara; Pierre Cordelier; Nicolas Bery
Journal:  Antibodies (Basel)       Date:  2022-07-12

Review 6.  mRNA as novel technology for passive immunotherapy.

Authors:  Thomas Schlake; Andreas Thess; Moritz Thran; Ingo Jordan
Journal:  Cell Mol Life Sci       Date:  2018-10-17       Impact factor: 9.261

Review 7.  A tale of two specificities: bispecific antibodies for therapeutic and diagnostic applications.

Authors:  Hannah Byrne; Paul J Conroy; James C Whisstock; Richard J O'Kennedy
Journal:  Trends Biotechnol       Date:  2013-10-02       Impact factor: 19.536

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.